Yes, paper should be soon but.. it's not a company that stands to benefit financially; it's one of the best run randomized trials. I don't see how they can ethically sit on this news given the findings. We also abruptly halt trials before the paper for similar levels of harms.
I'm for wariness. We're in a weird environment, have to take things case by case. I was publicly warning against the (observational) Lancet study of HCQ harms weeks before it became clear that the data was likely fraudulent. Despite Lancet being top journal, it didn't seem right!
-
-
OTOH, this one is not a company. Instead top-notch researchers and true and well-powered RCT. There is precedent for abrupt announcement, especially as governments/practitioners have to get ready. Prevent hoarding, etc. Still, agree, paper soon will guide clinical practice.
-
We've amazing preprints, we've had terrible peer-reviewed articles, we've had terrible (Harvard!) preprint study retweeted by POTUS (probably no amount of correction will work). It's not the usual environment.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.